Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial Medical Dialogues Bureau3 Nov 2019 3:30 AM GMTBristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to...
Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel Medical Dialogues Bureau28 July 2019 3:47 AM GMTSales of Eliquis, which Bristol-Myers shares with Pfizer Inc (PFE.N), rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both...
Bristols drug cocktail cuts kidney cancer death risk 37 percent Ruby Khatun Khatun14 Sep 2017 3:55 AM GMTMADRID: A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients,...
After melanoma surgery, Bristols Opdivo offers new care standard Ruby Khatun Khatun12 Sep 2017 3:45 AM GMTMADRID: Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients...
Bristol-Myers stops kidney cancer drug test after early success Ruby Khatun Khatun11 Sep 2017 5:18 AM GMTBristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end...
